Arpeggio Bio
Arpeggio Bio develops drugs targeting transcription factors using AI…
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
- Website
- arpeggiobio.com
- City
- Boulder
- Country
- United States
- YC batch
- Summer 2019
- Team
- 20 people
- Stage
- Early stage
- AI-native
- Yes
Compiled from public sources with help from automated tools, including AI, so details can be out of date. How we build profiles.
More Health & bio in Boulder
Claim this profile
Free and instant: prove you run arpeggiobio.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Arpeggio Bio across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Arpeggio Bio's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
